Study of Danicopan in Participants With Hepatic Impairment

Exclusion Criteria

• •Evidence of any other clinically significant deviation from normal in a clinical laboratory for the match-controlled participants and laboratory findings beyond those that are consistent with the degree of HI from hepatic participants.
• •History of any medical or psychiatric condition or disease.
• •Any previous procedure that could alter the absorption or excretion of orally administered drugs.
• •Body temperature greater than or equal to 38 degrees centigrade on Day -1 or Day 1 prior to dosing; history of febrile illness or other evidence of infection within 14 days prior to dosing.
• •History or presence of drug or alcohol abuse within 6 months prior to dosing; current tobacco/nicotine user; positive for alcohol and/or drugs-of-abuse at Screening or check in.
• •Participants who have received eculizumab at any dose or interval within the past 75 days.
• •Participation in any other investigational study drug trial 30 days before dosing.
• •Donation of whole blood from 3 months before dosing or of plasma from 30 days before dosing; receipt of blood products within 6 months before dosing.
• •HI Participants:
• •Any acute or chronic non-hepatic condition that would limit the participant's ability to participate in this study.
• •Any other unspecified reason that would make the participant unsuitable for enrollment.
• •Any screening laboratory evaluation outside the laboratory reference ranges not related to HI.
• •Fluctuating or rapidly deteriorating hepatic function within the screening period and up to 30 days prior to Day 1.
• •History of chronic liver disease due to Wilson's disease.
• •History of liver or other solid organ transplants.
• •Healthy Participants:
• •Clinical laboratory evaluations outside of the reference range at Screening or check-in.
• •Evidence of acute or chronic liver disease.
• •Use of any prescription medications/products within 14 days prior to dosing.
• •Use of over-the-counter, nonprescription preparations within 7 days prior to dosing.
• •Evidence of chronic HBV or chronic HCV infection.